Entero Therapeutics, INC S-1 registration statements

GridAI Technologies Corp. has entered into a Securities Purchase Agreement to sell approximately $5.25 million of its shares and warrants to various purchasers.

GridAI Technologies Corp. has filed an S-1/A amendment to register for resale up to 9,908,766 shares of its common stock by selling stockholders.

Entero Therapeutics files S-1/A for resale of 4.9M shares, rescinds ImmunogenX merger to focus on Adrulipase development, and faces significant financial and Nasdaq compliance challenges.

Entero Therapeutics files an S-1 registration statement for the resale of 4.9M common shares, signaling a strategic pivot to its Adrulipase program while navigating significant financial challenges and Nasdaq compliance issues.

Entero Therapeutics, Inc. is seeking to raise approximately $4 million through a public offering of common stock and pre-funded warrants to fund operations and advance its lead drug candidate, Adrulipase, while navigating severe financial constraints and the rescission of a recent merger.

Entero Therapeutics, Inc. is offering 12 million shares of common stock or pre-funded warrants to raise approximately $6 million, primarily to fund its lead drug candidate Adrulipase and address significant financial liabilities, while also unwinding a recent merger with ImmunogenX, Inc.

Entero Therapeutics, Inc. is offering 15.2 million shares and pre-funded warrants to raise approximately $4 million, aiming to fund its lead drug candidate Adrulipase and address significant financial challenges, including a planned rescission of its ImmunogenX merger.

Entero Therapeutics seeks to raise capital through a common stock and pre-funded warrant offering to fund the development of its lead drug candidate, Adrulipase, and manage existing liabilities.